Skip to main content

Table 4 Comparison of the sample sizes and joinpoint estimates, presented with 95% confidence intervals, for all analyses

From: What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink

 

Probable AD

Any AD

Any dementia

Source

Main analysis

Additional file 3

Additional file 3

Diagnoses

Probable AD

Probable AD

Possible AD

Probable AD

Possible AD

Non-AD and mixed dementias

AChE inhibitors

Eligible: 10,456

Treated: 5019

Joinpoint 1: Oct 2012

(Sep 2011–Apr 2013)

Joinpoint 2: May 2013

(Nov 2012–Apr 2014)

Eligible: 21,342

Treated: 6449

Joinpoint 1: Jun 1999

(Apr 1998–Dec 2000)

Joinpoint 2: Jun 2001

(Sep 2000–Mar 2002)

Eligible: 38,650

Treated: 9896

Joinpoint 1: Aug 2000

(Jun 1998–Nov 2000)

Joinpoint 2: Jan 2001

(Sep 2000–Nov 2001)

NMDA receptor antagonists

Eligible: 9964

Treated: 1052

Joinpoint 1: Mar 2011

(Aug 2010–Apr 2011)

Joinpoint 2: Jun 2011

(Apr 2011–Nov 2011)

Eligible: 18,930

Treated: 1309

Joinpoint 1: Sep 2010

(Dec 2009–Apr 2011)

Joinpoint 2: Nov 2011

(Apr 2011–Mar 2012)

Eligible: 35,625

Treated: 1961

Joinpoint 1: Aug 2010

(Nov 2009–Dec 2010)

Joinpoint 2: Nov 2011

(Aug 2011–Mar 2012)

  1. AChE Acetylcholinesterase, AD Alzheimer’s disease, NMDA N-methyl-d-aspartate